Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
A New Scientific Breakthrough Addressing Multiple Cancers Oren Gilad President and CEO [email protected] 215-589-6356 Bernard Rudnick Chief Financial Officer [email protected] 302-981-9001 Cancer drug sales exceed $100 billion in the US $300 billion market - $100 billion is chemotherapy Addressable market at $40 billion Aggressive cancers have poor or absent solutions Only 2 of 100 largest pharmas have Phase 1 ATR data Orally available - drives higher prescribing activity Lead molecule, ATRN-119, is a Best-In-Class ATR inhibitor Water soluble, orally bioavailable, highly potent Addressing a wide spectrum of cancers; reimbursable Non-Confidential 2 ATRN-119 Single Agent and Combinational Therapy: Indication of Efficacy Without Adverse Side Effects Human BRCA2-mutant Ovarian Cancer PDX 900 Tumor volume (mm3) 800 Control 700 600 500 ATRN-119 Olaparib 400 300 200 ATRN-119 + Olaparib 100 0 0 1 2 3 4 Time (weeks) 5 6 Simply put, Atrin’s non-optimized molecule in combination with the usual drug took tumor volume to zero in a cancer in which that has never been observed Contact Non-Confidential information 3 ATRN-119 Anti-Tumor Highlights Oral formulation Higher prescribing rates High potency & specificity Reduced clinical risk Biomarkers 6 weeks, then life-long maintenance Superior pharmacoeconomics Reimbursable under existing codes Highly effective single agent Combination with other therapies Effective in a wide spectrum of cancers Potential low side effects Oncogenic stress (Ras, Myc) Alternative lengthening of telomeres (ALT) Defects in Homologous Recombination (HR) pathway (ATM, BRCA1, or BRCA2 deficiency) Non-Confidential 4 Atrin’s Team, Board Members and Advisors Oren Gilad, Ph.D – Co-Founder and CEO Plus Stellar Board Serial entrepreneur Founded and sold two companies Named 2015 EY Entrepreneur Of The Year Greater Philadelphia Finalist Bernard Rudnick – CFO & Strategic Advisor Experienced Biotech C-Level executive, Keiretsu Member Facilitated exits and transactions valued over $7 billion Rifat Pamukcu, M.D. – Chief Medical Advisor President & CEO of Midway Pharmaceutical President & CEO of RxMP Therapeutics Founder, Director and Chief Science Officer of Cell Pathways (NASDAQ:CLPA, acquired by OSI Pharmaceuticals) Hank Breslin – Head of Chemistry Inventor of recently approved IBS-D drug Viberzi (Eluxadoline) Former chemist Janssen, J&J and Cephalon Non-Confidential 5 Company Overview and Value Proposition Platform Technology Licensed from the U of Pennsylvania – ROYALTY FREE ATR Kinase is a Validated Target Clear genetic and biochemical rational for developing drugs that inhibit the ATR kinase Advanced Lead Program ATRN-119 is a potent ATR kinase inhibitor less than 18 months from first in human trials Multiple Shots On Goal Portfolio of additional oncology small molecule drug candidates encompassing multiple mechanisms of action Personalized Medicine Approach Biomarker identifies patients with the highest probability of responding to ATRN-119 Strong Team Management team and advisory board have deep corporate and drug development and investment expertise Leaders of the field First to validate ATR as a target Non-Confidential 6 Seeking Strategic Partner Oren Gilad President and CEO [email protected] 215-589-6356 Bernard Rudnick Chief Financial Officer [email protected] 302-981-9001